Download Image
    
Share
  
Post
Brilacidin for COVID-19
1 study with 120 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Brilacidin
No significant improvements are seen in meta analysis to date.
COVID-19 Brilacidin studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Mortality 0% RCTs 0% Late 0% Favorsbrilacidin Favorscontrol
Brilacidin is a small molecule host defense protein (HDP) mimetic with broad-spectrum antiviral and anti-inflammatory properties, potentially beneficial for COVID-19 by disrupting viral integrity and blocking viral entry via host cell heparan sulfate proteoglycans (HSPGs).
Jul 30
2021
 Innovation Pharmaceuticals, NCT04784897 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19
no change in mortality (p=1), 33% higher combined mortality/intubation (p=1), and 20% worse recovery (p=1). RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin.